IRCT20200707048040N1尚未招募3 期
Evaluation of the efficacy and safety of Purslane (Portulaca oleracea) Product on Clinical Symptoms of Mild to Moderate Chronic Hand Dermatitis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 70 years（—）
- 性别
- All
入选标准
- •Patients with chronic unilateral or bilateral hand dermatitis, including occupational dermatitis, allergic dermatitis or irritative dermatitis
- •Age range 18 to 70 years
- •Willingness and satisfaction to participate in the study
- •Referred to traditional medicine center
排除标准
- •Breastfeeding
- •Patients with severe dermatitis
- •Patients with underlying diseases such as cardiovascular failure, diabetes, immune deficiency, autoimmune diseases, spinal cord diseases
- •Patients taking medication for their other illnesses
- •Patients who develop another acute illness during treatment
- •Patients who have an infection at the site of their dermatitis
- •Patients who are allergic to Portulaca oleracea
研究者
相似试验
已完成
不适用
A clinical study on the efficacy and safety of pursuing irradiation in stereotactic body radiotherapy for the lungung cancerJPRN-UMIN000005324Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University35
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide on Acne ScarsPolynucleotide, Acne scarAcne scarTCTR20230213003SW HEALTHCARE CO.,LTD27
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide for Facial Rejuvenation in ThailandHealthyPolynucleotide, Facial RejuvenationTCTR20230213002SW HEALTHCARE CO.,LTD25
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide for Periorbital Rejuvenation in ThailandHealthyPolynucleotide, Periorbital RejuvenationTCTR20230214003SW HEALTHCARE CO.,LTD25
已完成
3 期
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Parsaclisib Plus Investigator's Choice of Either Rituximab or Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma and Marginal Zone LymphomaJPRN-jRCT2031210296eda Eiji